GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ULTA · Nov 2, 2024

Ulta Beauty, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001558370-24-016048General Corporate
Capex intensity95thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

4.51% · OPTIONAL · VALID

Operating cash generation5thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-2.25% · OPTIONAL · VALID

Revenue growth25thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

1.65% · CORE · VALID

Gross margin70thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

39.75% · CORE · VALID

Operating margin30thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

12.59% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History62 statesSelf-history eligible
Period transition

What moved in the state?

Capex Intensity Increased
Previous
3.73%
Current
4.51%
Delta
0.78%
Cash Generation Decreased
Previous
7.82%
Current
-2.25%
Delta
-10.07%
Growth Increased
Previous
0.88%
Current
1.65%
Delta
0.77%
Margin Increased
Previous
38.33%
Current
39.75%
Delta
1.42%
Profitability Decreased
Previous
12.90%
Current
12.59%
Delta
-0.31%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.